Loading…
Deciphering the heterogeneity dominated by tumor-associated macrophages for survival prognostication and prediction of immunotherapy response in lung adenocarcinoma
Tumor-associated macrophages (TAMs) are a specific subset of macrophages that reside inside the tumor microenvironment. The dynamic interplay between TAMs and tumor cells plays a crucial role in the treatment response and prognosis of lung adenocarcinoma (LUAD). The study aimed to examine the associ...
Saved in:
| Published in: | Scientific reports 2024-04, Vol.14 (1), p.9276-9276, Article 9276 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | cdi_FETCH-LOGICAL-c448t-43deca5e3991e6657339f8f0fe71ffb7572e035e1d7c75f68eda57f2522eacb23 |
| container_end_page | 9276 |
| container_issue | 1 |
| container_start_page | 9276 |
| container_title | Scientific reports |
| container_volume | 14 |
| creator | Sun, Jiazheng Guo, Hehua Nie, Yalan Zhou, Sirui Zeng, Yulan Sun, Yalu |
| description | Tumor-associated macrophages (TAMs) are a specific subset of macrophages that reside inside the tumor microenvironment. The dynamic interplay between TAMs and tumor cells plays a crucial role in the treatment response and prognosis of lung adenocarcinoma (LUAD). The study aimed to examine the association between TAMs and LUAD to advance the development of targeted strategies and immunotherapeutic approaches for treating this type of lung cancer. The study employed single-cell mRNA sequencing data to characterize the immune cell composition of LUAD and delineate distinct subpopulations of TAMs. The "BayesPrism" and "Seurat" R packages were employed to examine the association between these subgroups and immunotherapy and clinical features to identify novel immunotherapy biomarkers. Furthermore, a predictive signature was generated to forecast patient prognosis by examining the gene expression profile of immunotherapy-associated TAMs subsets and using 104 machine-learning techniques. A comprehensive investigation has shown the existence of a hitherto unidentified subgroup of TAMs known as RGS1 + TAMs, which has been found to have a strong correlation with the efficacy of immunotherapy and the occurrence of tumor metastasis in LUAD patients. CD83 was identified CD83 as a distinct biomarker for the expression of RGS1 + TAMs, showcasing its potential utility as an indicator for immunotherapeutic interventions. Furthermore, the prognostic capacity of the RTMscore signature, encompassing three specific mRNA (NR4A2, MMP14, and NPC2), demonstrated enhanced robustness when contrasted against the comprehensive collection of 104 features outlined in the published study. CD83 has potential as an immunotherapeutic biomarker. Meanwhile, The RTMscore signature established in the present study might be beneficial for survival prognostication. |
| doi_str_mv | 10.1038/s41598-024-60132-4 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_1425c641fafb404e92fb2f12a514e0d1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_1425c641fafb404e92fb2f12a514e0d1</doaj_id><sourcerecordid>3045114724</sourcerecordid><originalsourceid>FETCH-LOGICAL-c448t-43deca5e3991e6657339f8f0fe71ffb7572e035e1d7c75f68eda57f2522eacb23</originalsourceid><addsrcrecordid>eNpdkstuFDEQRVsIRKKQH2CBLLFh0-BnP1YIhVekSGxgbVXb5RmPuu3G7h5p_ocPxTMTogRvbJevj6tct6peM_qeUdF9yJKpvqspl3VDmeC1fFZdcipVzQXnzx-tL6rrnHe0DMV7yfqX1YXoGiVayS-rP5_R-HmLyYcNWbZItrhgihsM6JcDsXHyARa0ZDiQZZ1iqiHnaPwpNoFJcd7CBjNxMZG8pr3fw0jmQggxL97A4mMgEGyJofXmtI2O-GlaQywPJpgPJGGeY8hIfCDjWjIBiyEaSMaHOMGr6oWDMeP1_XxV_fr65efN9_rux7fbm093tZGyW2opLBpQKPqeYdOoVojedY46bJlzQ6tajlQoZLY1rXJNhxZU67jiHMEMXFxVt2eujbDTc_ITpIOO4PUpENNGQypFjaiZ5Mo0kjlwg6QSe-4G7hgHxSRSywrr45k1r8OE1mBYEoxPoE9Pgt_qTdxrVtrbN40shHf3hBR_r5gXPflscBwhYFyzFqXBjMmWH6Vv_5Pu4ppC-aujqlOd4JIWFT-rStdyTugesmFUH02lz6bSxVT6ZCp9RL95XMfDlX8WEn8B_D_NUg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3048583240</pqid></control><display><type>article</type><title>Deciphering the heterogeneity dominated by tumor-associated macrophages for survival prognostication and prediction of immunotherapy response in lung adenocarcinoma</title><source>Publicly Available Content Database</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><source>Springer Nature - nature.com Journals - Fully Open Access</source><creator>Sun, Jiazheng ; Guo, Hehua ; Nie, Yalan ; Zhou, Sirui ; Zeng, Yulan ; Sun, Yalu</creator><creatorcontrib>Sun, Jiazheng ; Guo, Hehua ; Nie, Yalan ; Zhou, Sirui ; Zeng, Yulan ; Sun, Yalu</creatorcontrib><description>Tumor-associated macrophages (TAMs) are a specific subset of macrophages that reside inside the tumor microenvironment. The dynamic interplay between TAMs and tumor cells plays a crucial role in the treatment response and prognosis of lung adenocarcinoma (LUAD). The study aimed to examine the association between TAMs and LUAD to advance the development of targeted strategies and immunotherapeutic approaches for treating this type of lung cancer. The study employed single-cell mRNA sequencing data to characterize the immune cell composition of LUAD and delineate distinct subpopulations of TAMs. The "BayesPrism" and "Seurat" R packages were employed to examine the association between these subgroups and immunotherapy and clinical features to identify novel immunotherapy biomarkers. Furthermore, a predictive signature was generated to forecast patient prognosis by examining the gene expression profile of immunotherapy-associated TAMs subsets and using 104 machine-learning techniques. A comprehensive investigation has shown the existence of a hitherto unidentified subgroup of TAMs known as RGS1 + TAMs, which has been found to have a strong correlation with the efficacy of immunotherapy and the occurrence of tumor metastasis in LUAD patients. CD83 was identified CD83 as a distinct biomarker for the expression of RGS1 + TAMs, showcasing its potential utility as an indicator for immunotherapeutic interventions. Furthermore, the prognostic capacity of the RTMscore signature, encompassing three specific mRNA (NR4A2, MMP14, and NPC2), demonstrated enhanced robustness when contrasted against the comprehensive collection of 104 features outlined in the published study. CD83 has potential as an immunotherapeutic biomarker. Meanwhile, The RTMscore signature established in the present study might be beneficial for survival prognostication.</description><identifier>ISSN: 2045-2322</identifier><identifier>EISSN: 2045-2322</identifier><identifier>DOI: 10.1038/s41598-024-60132-4</identifier><identifier>PMID: 38653742</identifier><language>eng</language><publisher>England: Nature Publishing Group</publisher><subject>Adenocarcinoma ; Adenocarcinoma of Lung - genetics ; Adenocarcinoma of Lung - immunology ; Adenocarcinoma of Lung - mortality ; Adenocarcinoma of Lung - pathology ; Adenocarcinoma of Lung - therapy ; Antigens, CD - genetics ; Antigens, CD - metabolism ; Biomarkers ; Biomarkers, Tumor ; Cancer ; CD83 antigen ; Female ; Gene expression ; Gene Expression Regulation, Neoplastic ; Heterogeneity ; Humans ; Immunotherapy ; Immunotherapy - methods ; Lung adenocarcinoma ; Lung cancer ; Lung diseases ; Lung Neoplasms - immunology ; Lung Neoplasms - mortality ; Lung Neoplasms - pathology ; Lung Neoplasms - therapy ; Lungs ; Macrophages ; Male ; Medical prognosis ; Metastases ; Neoplasms ; Patients ; Prognosis ; Prognostic signature ; Subpopulations ; Tumor cells ; Tumor microenvironment ; Tumor Microenvironment - immunology ; Tumor-associated macrophages ; Tumor-Associated Macrophages - immunology ; Tumor-Associated Macrophages - metabolism ; Tumors</subject><ispartof>Scientific reports, 2024-04, Vol.14 (1), p.9276-9276, Article 9276</ispartof><rights>2024. The Author(s).</rights><rights>The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c448t-43deca5e3991e6657339f8f0fe71ffb7572e035e1d7c75f68eda57f2522eacb23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/3048583240/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/3048583240?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,315,733,786,790,891,25783,27957,27958,37047,37048,44625,53827,53829,75483</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38653742$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sun, Jiazheng</creatorcontrib><creatorcontrib>Guo, Hehua</creatorcontrib><creatorcontrib>Nie, Yalan</creatorcontrib><creatorcontrib>Zhou, Sirui</creatorcontrib><creatorcontrib>Zeng, Yulan</creatorcontrib><creatorcontrib>Sun, Yalu</creatorcontrib><title>Deciphering the heterogeneity dominated by tumor-associated macrophages for survival prognostication and prediction of immunotherapy response in lung adenocarcinoma</title><title>Scientific reports</title><addtitle>Sci Rep</addtitle><description>Tumor-associated macrophages (TAMs) are a specific subset of macrophages that reside inside the tumor microenvironment. The dynamic interplay between TAMs and tumor cells plays a crucial role in the treatment response and prognosis of lung adenocarcinoma (LUAD). The study aimed to examine the association between TAMs and LUAD to advance the development of targeted strategies and immunotherapeutic approaches for treating this type of lung cancer. The study employed single-cell mRNA sequencing data to characterize the immune cell composition of LUAD and delineate distinct subpopulations of TAMs. The "BayesPrism" and "Seurat" R packages were employed to examine the association between these subgroups and immunotherapy and clinical features to identify novel immunotherapy biomarkers. Furthermore, a predictive signature was generated to forecast patient prognosis by examining the gene expression profile of immunotherapy-associated TAMs subsets and using 104 machine-learning techniques. A comprehensive investigation has shown the existence of a hitherto unidentified subgroup of TAMs known as RGS1 + TAMs, which has been found to have a strong correlation with the efficacy of immunotherapy and the occurrence of tumor metastasis in LUAD patients. CD83 was identified CD83 as a distinct biomarker for the expression of RGS1 + TAMs, showcasing its potential utility as an indicator for immunotherapeutic interventions. Furthermore, the prognostic capacity of the RTMscore signature, encompassing three specific mRNA (NR4A2, MMP14, and NPC2), demonstrated enhanced robustness when contrasted against the comprehensive collection of 104 features outlined in the published study. CD83 has potential as an immunotherapeutic biomarker. Meanwhile, The RTMscore signature established in the present study might be beneficial for survival prognostication.</description><subject>Adenocarcinoma</subject><subject>Adenocarcinoma of Lung - genetics</subject><subject>Adenocarcinoma of Lung - immunology</subject><subject>Adenocarcinoma of Lung - mortality</subject><subject>Adenocarcinoma of Lung - pathology</subject><subject>Adenocarcinoma of Lung - therapy</subject><subject>Antigens, CD - genetics</subject><subject>Antigens, CD - metabolism</subject><subject>Biomarkers</subject><subject>Biomarkers, Tumor</subject><subject>Cancer</subject><subject>CD83 antigen</subject><subject>Female</subject><subject>Gene expression</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Heterogeneity</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Immunotherapy - methods</subject><subject>Lung adenocarcinoma</subject><subject>Lung cancer</subject><subject>Lung diseases</subject><subject>Lung Neoplasms - immunology</subject><subject>Lung Neoplasms - mortality</subject><subject>Lung Neoplasms - pathology</subject><subject>Lung Neoplasms - therapy</subject><subject>Lungs</subject><subject>Macrophages</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Metastases</subject><subject>Neoplasms</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Prognostic signature</subject><subject>Subpopulations</subject><subject>Tumor cells</subject><subject>Tumor microenvironment</subject><subject>Tumor Microenvironment - immunology</subject><subject>Tumor-associated macrophages</subject><subject>Tumor-Associated Macrophages - immunology</subject><subject>Tumor-Associated Macrophages - metabolism</subject><subject>Tumors</subject><issn>2045-2322</issn><issn>2045-2322</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdkstuFDEQRVsIRKKQH2CBLLFh0-BnP1YIhVekSGxgbVXb5RmPuu3G7h5p_ocPxTMTogRvbJevj6tct6peM_qeUdF9yJKpvqspl3VDmeC1fFZdcipVzQXnzx-tL6rrnHe0DMV7yfqX1YXoGiVayS-rP5_R-HmLyYcNWbZItrhgihsM6JcDsXHyARa0ZDiQZZ1iqiHnaPwpNoFJcd7CBjNxMZG8pr3fw0jmQggxL97A4mMgEGyJofXmtI2O-GlaQywPJpgPJGGeY8hIfCDjWjIBiyEaSMaHOMGr6oWDMeP1_XxV_fr65efN9_rux7fbm093tZGyW2opLBpQKPqeYdOoVojedY46bJlzQ6tajlQoZLY1rXJNhxZU67jiHMEMXFxVt2eujbDTc_ITpIOO4PUpENNGQypFjaiZ5Mo0kjlwg6QSe-4G7hgHxSRSywrr45k1r8OE1mBYEoxPoE9Pgt_qTdxrVtrbN40shHf3hBR_r5gXPflscBwhYFyzFqXBjMmWH6Vv_5Pu4ppC-aujqlOd4JIWFT-rStdyTugesmFUH02lz6bSxVT6ZCp9RL95XMfDlX8WEn8B_D_NUg</recordid><startdate>20240423</startdate><enddate>20240423</enddate><creator>Sun, Jiazheng</creator><creator>Guo, Hehua</creator><creator>Nie, Yalan</creator><creator>Zhou, Sirui</creator><creator>Zeng, Yulan</creator><creator>Sun, Yalu</creator><general>Nature Publishing Group</general><general>Nature Publishing Group UK</general><general>Nature Portfolio</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20240423</creationdate><title>Deciphering the heterogeneity dominated by tumor-associated macrophages for survival prognostication and prediction of immunotherapy response in lung adenocarcinoma</title><author>Sun, Jiazheng ; Guo, Hehua ; Nie, Yalan ; Zhou, Sirui ; Zeng, Yulan ; Sun, Yalu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c448t-43deca5e3991e6657339f8f0fe71ffb7572e035e1d7c75f68eda57f2522eacb23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adenocarcinoma</topic><topic>Adenocarcinoma of Lung - genetics</topic><topic>Adenocarcinoma of Lung - immunology</topic><topic>Adenocarcinoma of Lung - mortality</topic><topic>Adenocarcinoma of Lung - pathology</topic><topic>Adenocarcinoma of Lung - therapy</topic><topic>Antigens, CD - genetics</topic><topic>Antigens, CD - metabolism</topic><topic>Biomarkers</topic><topic>Biomarkers, Tumor</topic><topic>Cancer</topic><topic>CD83 antigen</topic><topic>Female</topic><topic>Gene expression</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Heterogeneity</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Immunotherapy - methods</topic><topic>Lung adenocarcinoma</topic><topic>Lung cancer</topic><topic>Lung diseases</topic><topic>Lung Neoplasms - immunology</topic><topic>Lung Neoplasms - mortality</topic><topic>Lung Neoplasms - pathology</topic><topic>Lung Neoplasms - therapy</topic><topic>Lungs</topic><topic>Macrophages</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Metastases</topic><topic>Neoplasms</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Prognostic signature</topic><topic>Subpopulations</topic><topic>Tumor cells</topic><topic>Tumor microenvironment</topic><topic>Tumor Microenvironment - immunology</topic><topic>Tumor-associated macrophages</topic><topic>Tumor-Associated Macrophages - immunology</topic><topic>Tumor-Associated Macrophages - metabolism</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sun, Jiazheng</creatorcontrib><creatorcontrib>Guo, Hehua</creatorcontrib><creatorcontrib>Nie, Yalan</creatorcontrib><creatorcontrib>Zhou, Sirui</creatorcontrib><creatorcontrib>Zeng, Yulan</creatorcontrib><creatorcontrib>Sun, Yalu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Science Journals</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Scientific reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sun, Jiazheng</au><au>Guo, Hehua</au><au>Nie, Yalan</au><au>Zhou, Sirui</au><au>Zeng, Yulan</au><au>Sun, Yalu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Deciphering the heterogeneity dominated by tumor-associated macrophages for survival prognostication and prediction of immunotherapy response in lung adenocarcinoma</atitle><jtitle>Scientific reports</jtitle><addtitle>Sci Rep</addtitle><date>2024-04-23</date><risdate>2024</risdate><volume>14</volume><issue>1</issue><spage>9276</spage><epage>9276</epage><pages>9276-9276</pages><artnum>9276</artnum><issn>2045-2322</issn><eissn>2045-2322</eissn><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><abstract>Tumor-associated macrophages (TAMs) are a specific subset of macrophages that reside inside the tumor microenvironment. The dynamic interplay between TAMs and tumor cells plays a crucial role in the treatment response and prognosis of lung adenocarcinoma (LUAD). The study aimed to examine the association between TAMs and LUAD to advance the development of targeted strategies and immunotherapeutic approaches for treating this type of lung cancer. The study employed single-cell mRNA sequencing data to characterize the immune cell composition of LUAD and delineate distinct subpopulations of TAMs. The "BayesPrism" and "Seurat" R packages were employed to examine the association between these subgroups and immunotherapy and clinical features to identify novel immunotherapy biomarkers. Furthermore, a predictive signature was generated to forecast patient prognosis by examining the gene expression profile of immunotherapy-associated TAMs subsets and using 104 machine-learning techniques. A comprehensive investigation has shown the existence of a hitherto unidentified subgroup of TAMs known as RGS1 + TAMs, which has been found to have a strong correlation with the efficacy of immunotherapy and the occurrence of tumor metastasis in LUAD patients. CD83 was identified CD83 as a distinct biomarker for the expression of RGS1 + TAMs, showcasing its potential utility as an indicator for immunotherapeutic interventions. Furthermore, the prognostic capacity of the RTMscore signature, encompassing three specific mRNA (NR4A2, MMP14, and NPC2), demonstrated enhanced robustness when contrasted against the comprehensive collection of 104 features outlined in the published study. CD83 has potential as an immunotherapeutic biomarker. Meanwhile, The RTMscore signature established in the present study might be beneficial for survival prognostication.</abstract><cop>England</cop><pub>Nature Publishing Group</pub><pmid>38653742</pmid><doi>10.1038/s41598-024-60132-4</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2045-2322 |
| ispartof | Scientific reports, 2024-04, Vol.14 (1), p.9276-9276, Article 9276 |
| issn | 2045-2322 2045-2322 |
| language | eng |
| recordid | cdi_doaj_primary_oai_doaj_org_article_1425c641fafb404e92fb2f12a514e0d1 |
| source | Publicly Available Content Database; PubMed Central; Free Full-Text Journals in Chemistry; Springer Nature - nature.com Journals - Fully Open Access |
| subjects | Adenocarcinoma Adenocarcinoma of Lung - genetics Adenocarcinoma of Lung - immunology Adenocarcinoma of Lung - mortality Adenocarcinoma of Lung - pathology Adenocarcinoma of Lung - therapy Antigens, CD - genetics Antigens, CD - metabolism Biomarkers Biomarkers, Tumor Cancer CD83 antigen Female Gene expression Gene Expression Regulation, Neoplastic Heterogeneity Humans Immunotherapy Immunotherapy - methods Lung adenocarcinoma Lung cancer Lung diseases Lung Neoplasms - immunology Lung Neoplasms - mortality Lung Neoplasms - pathology Lung Neoplasms - therapy Lungs Macrophages Male Medical prognosis Metastases Neoplasms Patients Prognosis Prognostic signature Subpopulations Tumor cells Tumor microenvironment Tumor Microenvironment - immunology Tumor-associated macrophages Tumor-Associated Macrophages - immunology Tumor-Associated Macrophages - metabolism Tumors |
| title | Deciphering the heterogeneity dominated by tumor-associated macrophages for survival prognostication and prediction of immunotherapy response in lung adenocarcinoma |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-21T00%3A46%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Deciphering%20the%20heterogeneity%20dominated%20by%20tumor-associated%20macrophages%20for%20survival%20prognostication%20and%20prediction%20of%20immunotherapy%20response%20in%20lung%20adenocarcinoma&rft.jtitle=Scientific%20reports&rft.au=Sun,%20Jiazheng&rft.date=2024-04-23&rft.volume=14&rft.issue=1&rft.spage=9276&rft.epage=9276&rft.pages=9276-9276&rft.artnum=9276&rft.issn=2045-2322&rft.eissn=2045-2322&rft_id=info:doi/10.1038/s41598-024-60132-4&rft_dat=%3Cproquest_doaj_%3E3045114724%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c448t-43deca5e3991e6657339f8f0fe71ffb7572e035e1d7c75f68eda57f2522eacb23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3048583240&rft_id=info:pmid/38653742&rfr_iscdi=true |